45 years! U.S. prescription drug prices fall for the first time

In developed countries, drug prices are also one of the focus of the government's attention, how to provide quality medical services, but also reduce the cost of national medical expenses, and do not hurt the enthusiasm of pharmaceutical companies research and development, the government is a great testThe U.Sprice of prescription drugs fell by 1 percent last year, though not much, but it was the first time in 45 years that the decline was largely due to a more generic drug tilt in the health care system and slower growth in branddrugsales, according to the Washington Postthe drug price study, conducted by the U.SCenters for Medicare and Medicaid Services (CMS), said it was the first time prescription drug prices had fallen, a result the New York Times called unprecedented since 1973, when drug prices fell 0.2 percent, the Washington Post, citing cmS, reported that overall prescription drug spending rose 2.5 percent to $355 billion in 2018, despite a 1 percent drop in retail prices, and overall, U.Shealth care spending climbed to $3.6 trillion in 2018, up 4.6 percentCMS report also notes that U.Shealth care spending accounts for nearly 18 percent of the U.Seconomy and $11,172 per person, according to a New York Times analysis, 9 percent of the $3.6 trillion in U.Shealth care spending is spent on prescription drugs outside hospitals, while prescription drug prices have fallen for the first time, U.Sefforts to lower drug prices continuethe CMS report comes as lawmakers in Congress and the government are working on different options to control the price of prescription drugs in the United States, and most of the legislation to be passed by the House and Senate is aimed at drugs covered by government-funded programs such as health insuranceHouse Speaker Nancy Pelosi plans to push ahead with her medicare pricing plan next week, proposing to link medics to the International Drug Price Index and punish drug companies that don't participate in the plan, and allow private insurers to participate in the medicare pricing structure, with a minimum vote expected as soon as next weekand the House plan was opposed by the pharmaceutical industry and some White House officials, stat reported that more than 100 CEOs of emerging biopharmaceutical companies opposed the Speaker's plan, which, if passed, would have dire consequences for the industry they believe the plan will stifle innovation and cause the company's new drugs being developed to lose money because of a lack of research and development funding, which is financed by profits from drug sales some White House officials also expressed support, even though the White House once supported a plan called the "beneficiary clause" to link the price of health-care drugs to the International Drug Price Index, but has now turned to a more bipartisan Senate plan that calls for pharmaceutical companies to pay rebates to health insurance if drug prices rise above inflation it seems that the game against drug prices will continue, and next year will remain the focus of society.